Neoadjuvant treatment is highly recommended for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC), given its well-established benefits in improving surgery outcome and survival1,2. This evidence concerns the gene ERBB2 and breast cancer.